Curis to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on March 31, 2025

Core Viewpoint - Curis, Inc. is set to report its fourth quarter 2024 financial and operational results on March 31, 2025, with a conference call scheduled for the same day [1]. Company Overview - Curis, Inc. is a biotechnology company focused on developing emavusertib (CA-4948), an orally available small molecule IRAK4 inhibitor [3]. - Emavusertib is currently being evaluated in multiple clinical studies, including the Phase 1/2 TakeAim Lymphoma study for relapsed/refractory primary central nervous system lymphoma (PCNSL) and the Phase 1/2 TakeAim Leukemia study for relapsed/refractory acute myeloid leukemia (AML) [3]. - The drug has received Orphan Drug Designation from the U.S. FDA for PCNSL, AML, and myelodysplastic syndrome (MDS), as well as from the European Commission for PCNSL [3]. - Curis has an exclusive license to emavusertib through a collaboration with Aurigene established in 2015 [3]. - The company also licensed its rights to Erivedge® to Genentech, which is commercializing the drug for advanced basal cell carcinoma [3].